QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NASDAQ:STRO

Sutro Biopharma - STRO Stock Forecast, Price & News

$7.11
-0.24 (-3.27%)
(As of 02/3/2023 05:19 PM ET)
Add
Compare
Today's Range
$7.07
$7.39
50-Day Range
$6.68
$8.45
52-Week Range
$3.33
$10.15
Volume
370,428 shs
Average Volume
615,310 shs
Market Capitalization
$408.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.67

Sutro Biopharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
176.6% Upside
$19.67 Price Target
Short Interest
Healthy
3.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.54) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

245th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

38th out of 169 stocks

STRO stock logo

About Sutro Biopharma (NASDAQ:STRO) Stock

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Stock News Headlines

Man hit by train on tracks at Sutro
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Sutro Biopharma, Inc. (STRO)
See More Headlines
Receive STRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STRO Company Calendar

Last Earnings
11/08/2022
Today
2/03/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STRO
Fax
N/A
Employees
224
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.67
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+176.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-105,540,000.00
Net Margins
-175.85%
Pretax Margin
-172.27%

Debt

Sales & Book Value

Annual Sales
$61.88 million
Book Value
$5.46 per share

Miscellaneous

Free Float
53,222,000
Market Cap
$408.61 million
Optionable
Not Optionable
Beta
0.88

Key Executives

  • William J. Newell
    President, Chief Executive Officer & Director
  • Edward C. Albini
    Chief Financial Officer & Secretary
  • Trevor Hallam
    Chief Scientific Officer & President-Research
  • Shabbir T. Anik
    Chief Technical Operations Officer
  • Craig Berman
    Vice President-Clinical Development













STRO Stock - Frequently Asked Questions

Should I buy or sell Sutro Biopharma stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares.
View STRO analyst ratings
or view top-rated stocks.

What is Sutro Biopharma's stock price forecast for 2023?

5 brokerages have issued 1 year target prices for Sutro Biopharma's stock. Their STRO share price forecasts range from $15.00 to $25.00. On average, they expect the company's stock price to reach $19.67 in the next year. This suggests a possible upside of 170.1% from the stock's current price.
View analysts price targets for STRO
or view top-rated stocks among Wall Street analysts.

How have STRO shares performed in 2023?

Sutro Biopharma's stock was trading at $8.08 at the beginning of the year. Since then, STRO shares have decreased by 9.9% and is now trading at $7.28.
View the best growth stocks for 2023 here
.

When is Sutro Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our STRO earnings forecast
.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) posted its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.22. The business earned $25.15 million during the quarter, compared to analysts' expectations of $11.35 million. Sutro Biopharma had a negative net margin of 175.85% and a negative trailing twelve-month return on equity of 53.85%.

What is William J. Newell's approval rating as Sutro Biopharma's CEO?

11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV).

When did Sutro Biopharma IPO?

(STRO) raised $75 million in an IPO on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Sutro Biopharma's stock symbol?

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Who are Sutro Biopharma's major shareholders?

Sutro Biopharma's stock is owned by many different retail and institutional investors. Top institutional shareholders include New York State Common Retirement Fund (0.05%), Allspring Global Investments Holdings LLC (0.05%), Bailard Inc. (0.04%), SG Americas Securities LLC (0.03%), ProShare Advisors LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Arturo Md Molina, John Gordon Freund, Nicki Vasquez, Trevor Hallam and William J Newell.
View institutional ownership trends
.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sutro Biopharma's stock price today?

One share of STRO stock can currently be purchased for approximately $7.28.

How much money does Sutro Biopharma make?

Sutro Biopharma (NASDAQ:STRO) has a market capitalization of $418.38 million and generates $61.88 million in revenue each year. The company earns $-105,540,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis.

How many employees does Sutro Biopharma have?

The company employs 224 workers across the globe.

How can I contact Sutro Biopharma?

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The official website for the company is www.sutrobio.com. The company can be reached via phone at (650) 392-8412 or via email at ajchang@sutrobio.com.

This page (NASDAQ:STRO) was last updated on 2/3/2023 by MarketBeat.com Staff